Allogeneic hematopoietic stem cell transplantation is often used to treat hematologic malignancies. The efficacy of this procedure is due to both myeloablative conditioning and graft-versus-leukemia (GVL). However, the disadvantages of allogeneic transplantation include graft-versus-host disease (GVHD), relapse from the original tumor, and patient susceptibility to opportunistic infections. Lately, allogeneic transplantation has been developed to treat solid tumors, with the expectation that graft-versus-tumor (GVT), like GVL, will have a significant anti-tumor effect. This effect has been demonstrated in renal carcinomas, and with less evidence in breast cancers. Five patients with malignant ovarian tumors resistant to chemotherapy underwent allogeneic transplantation, four from bone marrow, and one from peripheral blood stem cells. All donors were HLA-identical siblings. One patient received a myeloablative conditioning regimen, while the other four received a non-myeloablative regimen. Two patients received donor lymphocyte infusions (DLI). Four of the patients presented with acute or chronic GVHD associated with tumor regression of at least 50%. These tumor regressions were measured by CA-125 levels and CT scans. The fifth patient died of rapid progression just after transplantation. Of the four transplantation survivors, three received a non-myeloablative regimen which did not seem to reduce treatment effectiveness. While it did reduce toxicity, one of these patients died of GVHD after 127 days. DLI was administered to two patients. These infusions seemed to promote GVHD which was able to control disease progression for one patient and had no apparent effect on the other. Allograft of hematopoietic stem cells might be of interest in ovarian cancer. The results in one patient also suggest that DLI may be an effective immunotherapy, although doses and timing need to be determined. The number of cases presented is small, however, and clinical experience on a larger scale will be required to determine the real clinical efficacy of graft versus cancerous ovarian cells.
Ovarian carcinomas are known for being initially chemosensitive tumors. 1, 2 A clinical complete remission after induction chemotherapy is usually achieved. However, even if chemotherapy regimens improve median survival, disease eradication is rarely obtained. 3, 4 New drugs, especially paclitaxel, have improved the prognosis. [5] [6] [7] Highdose chemotherapy regimens also appear to increase time to relapse and overall survival due to a favorable doseresponse. 8, 9 Some immunotherapy agents such as intraperitoneal interleukin-2 (IL-2) have also been used with some success. 10, 11 These reports attest the possible immunogenicity of these tumors. In spite of these treatments, and of the initially obtained high complete response rates, prognosis of ovarian cancers remains poor, especially after they become chemoresistant.
Allogeneic stem cell transplantation for treatment of hematologic malignancies was originally based on the effects of a myeloablative regimen. After induction treatment, this procedure was supposed to eradicate the underlying disease. 12 Later, it was found that allogeneic cells were responsible for an immunologic response against the tumor called a graft-versus-leukemia (GVL) effect. 13 Immunologically competent T lymphocytes transplanted with the allograft are responsible for this effect. Evidence supporting this hypothesis includes: (1) lower risk of relapse and improved survival in patients receiving allogeneic hematopoietic cell transplants compared to those receiving autologous grafts; 14, 15 (2) higher risk of relapse in cases of syngeneic allograft; 16 (3) lower risk of relapse in patients with acute or chronic graft-versus-host disease (GVHD) compared to patients without GVHD; 17, 18 (4) higher risk of relapse after T cell-depleted compared with nondepleted allografts; [19] [20] [21] and (5) therapeutic effect of donor lymphocyte infusion (DLI). 22 However, to what extent the donor T cell population mediates a graft-versus-tumor (GVT) activity and GVHD remains unclear. Furthermore, target antigens for GVT activity are unknown.
The procedure is associated with a very high rate of toxicity, including GVHD and infections. Therefore, morbidity and mortality limit its indication for younger patients with good prognosis medical conditions and with minimal residual disease. In order to reduce toxicity, non-myeloablative regimens in combination with pre-and post-transplantation immunosuppression have recently been proposed. 23, 24 This procedure allows engraftment with stem cells from either bone marrow or peripheral blood. Immediately after the graft, mixed chimerism is obtained, which progressively evolves towards complete chimerism in approximately 90% of patients. 25 Therefore allogeneic transplantation is not based on chemotherapy or total body irradiation antitumor effects, but only on adoptive immunotherapy based on the GVT effect. DLI also induces GVT and reduces mixed chimerism. 26 Several observations can justify allogeneic transplantation in solid tumors: (1) there is no risk of reinfusing autologous malignant cells; (2) graft-versus-malignancy effects can target tissue-specific polymorphic antigens which are not derived from a hematopoietic lineage; and (3) some solid tumors are sensitive to immunotherapy, such as renal carcinoma, melanoma and (with less evidence) ovarian cancer. Some reports have already demonstrated evidence of a GVT effect in renal carcinoma and in breast cancer. [27] [28] [29] [30] Ovarian cancer might be a good model for allogeneic transplantation. In 2000 we reported a good tumor response associated with clinical GVHD. 31 Here, we report the follow-up of this observation with four additional patients.
Patients and methods

Patient and donor characteristics
Between May 1998 and March 2001, five consecutive patients with ovarian carcinoma received allogeneic stem cell transplantation from an HLA-identical sibling in a pilot study testing allogeneic transplantation in advanced solid tumors. All patients were included in this study after informed consent had been obtained. The trial was approved by the ethics review committee of Marseille, France.
The patients were required to have a related HLA-identical donor, be no more than 60 years of age, have a WHO performance status of 0 or 1 and have adequate organ function (serum creatinine concentration Ͻ1.5 mg/dl, absence of liver failure, ventricular ejection fraction у50% and forced expiratory volume in 1 s and diffusing capacity of carbon monoxide у50% of predicted values). The patients' disease was required to be chemoresistant.
Bone marrow from HLA-identical siblings for patients A, B, C and D was harvested, while the donor for patient E received filgrastim 5 mg/kg s.c. twice a day to mobilize peripheral blood progenitor cells (PBPC). Collection by two aphereses was performed on day Ϫ1 and day 0 of transplantation. A minimum of 4 ϫ 10 6 CD34 + cells/kg was required. No positive selection, T cell depletion, or cryopreservation procedures were performed.
Conditioning regimen, GVHD prophylaxis and supportive care
One patient (patient A) received myeloablative chemotherapy as a conditioning regimen (busulphan 16 mg/kg on days Ϫ7, Ϫ6 Ϫ5, and Ϫ4 and cyclophosphamide 60 mg/kg on days Ϫ3 and Ϫ2). Mesna 500 mg/m 2 was administered intravenously 30 min before the first injection of cyclophosphamide, and then at 2000 mg/m 2 as a continuous infusion over 24 h for 2 days. The other four patients (patients B, C, D and E) received a non-myeloablative regimen derived from the regimen described by Slavin et al. 23, 24 Patients B, C and D received busulphan (4 mg/kg a day on days Ϫ3 and Ϫ2), fludarabine (30 mg/m 2 on days Ϫ7, Ϫ6, Ϫ5, Ϫ4, Ϫ3 and Ϫ2) and antithymocyte globulin (ATG) (2.5 mg/kg on days Ϫ5, Ϫ4 and Ϫ3). Patient E received the same doses of fludarabine from days Ϫ7 to Ϫ2, of busulphan on days Ϫ4 and Ϫ3, but only 1 day of ATG on day Ϫ2.
Prophylaxis against GVHD consisted of cyclosporine, started at day Ϫ1. The recipients received a dose of 3 mg/kg/day intravenously. This dose was converted into oral dosing every 12 h when patients were able to leave the unit. Methylprednisolone and methotrexate were not given. In the absence of GVHD and the presence of residual or recurrent disease, cyclosporine doses were then reduced by 20% every 2 weeks. In the absence of immunosuppressive therapy and of GVHD, additional donor lymphocytes were infused with a maximum of three escalating doses, on days 90, 150, and 210 (0.5 ϫ 10 7 , 1 ϫ 10 7 and 5 ϫ 10 7 mononuclear cells/kg, respectively). The same donor used for the original transplant underwent leukapheresis without G-CSF.
Patients who developed grade 2 or greater acute GVHD were treated daily with methylprednisolone 2 mg/kg. 32 In cases where this was ineffective, anti-R-IL2 was administered. 33 Granulocyte colony-stimulating factor (G-CSF) was not given at any time.
Infection prophylaxis consisted of acyclovir and fluconazole. During neutropenia, intravenous antibiotics were administered in the event of fever or any other suspicion of infection. After granulocyte recovery to greater than 1.0 ϫ 10 9 /l, patients received prophylactic ganciclovir until day 120, if recipients or donors were seropositive for cytomegalovirus. For these patients, intravenous immunoglobulin (0.2 g/kg) was administered weekly for 100 days, and monthly for 1 year. Patients also received trimethoprim/sulfamethoxazole or aerosolized pentamidine for prophylaxis against Pneumocystis carinii and an oral ␤-lactamine antibiotic. Irradiated blood products were administered if the hemoglobin was less than 8 g/dl and the platelet count less than 20 ϫ 10 9 /l.
Evaluation of hematologic recovery, toxicity and tumor response
Hematologic recovery was evaluated by blood samples taken daily until day 30. Hematopoietic chimerism in allo-geneic recipients was determined at days 30, 60, 90 and before and after DLI by conventional cytogenetic analysis for sex-mismatched donor-recipient pairs, or by PCR-based analysis of VNTR polymorphisms in sex-matched cases.
Toxicities were evaluated according to the OMS common toxicity criteria. Severity of GVHD was graded according to the Glucksberg grade. 34, 35 A medical history and physical examinations were undertaken weekly until day 90 after exit from the unit and then every 2 weeks. Tumor responses were evaluated by CA-125 levels and CT scans, performed monthly for 6 months after stem cell transplantation and then every 4 months. Complete response (CR) was defined if all the measurable tumor disappeared for more than 1 month. A partial response (PR) was defined as a greater than 50% reduction in the sum of the products of the two greatest perpendicular diameters of each measurable lesion. Stable disease (SD) was defined as a Ͻ25% increase or a less than 50% reduction in that sum, and progression of disease (PD) as the appearance of new lesions or a greater than 25% increase in that sum.
Results
Patient and donor characteristics
The patients were all suffering from ovarian carcinoma. The median age was 43.5 years (range, 32-60). Details of patient characteristics are shown in Table 1 .
All patients had previously received conventional treatment for ovarian cancer, including surgery and chemotherapy with paclitaxel, platinum, doxorubicine and/or [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . In patient A, who received a myeloablative regimen, we observed the profoundest and longest neutropenia and thrombopenia.
Engraftment and chimerism
The four evaluable patients achieved complete hematopoietic engraftment, with complete chimerism confirmed at day 30.
Transplant-related adverse events and toxicities
No toxicity or infection more than grade I/II was observed. Patient B died 6 days after transplantation. Before transplantation, her refractory ovarian cancer was in slow progression. During the non-myeloablative regimen her disease advanced rapidly and she died of disease progression with no therapy-related toxicity. Tumor progression during Table 2 Post-transplantation course of the patients The four evaluable patients developed acute GVHD (aGVHD). All of them presented with stage 3 skin aGVHD. Patients A and D also suffered from stage 2 and stage 4 gastrointestinal aGVHD, respectively. They all responded to methylprednisolone therapy and anti-R-IL-2, except for patient D who died of gastrointestinal aGVHD at day 127.
Patient A developed chronic liver GVHD which was well tolerated and confirmed by biopsy. This chronic GVHD (cGVHD) was observed until 20 months after transplantation. Three donor lymphocyte infusions (DLI) were given after relapse in patients A and C. GVHD did not obviously recur in patient A, while patient C developed stage 3 skin cGVHD 10 days after the last intravenous infusion. She was not treated for 5 months and then received high doses of methylprednisolone because of progressive cutaneous cGVHD with ulceration.
Case reports
Patient A: Before transplantation the patient presented with abdominal tumor nodules (Figure 1a) , progressive pulmonary metastatic lesions and high CA-125 levels (Figure 1e ). The conditioning regimen consisted of myeloablative chemotherapy. At day 28 she presented with acute grade III GVHD involving the skin and digestive tract. Concurrently, the clinical symptoms disappeared, followed by normalization of CA-125 at day 60. A CT scan at day 90 showed a partial remission (Figure 1b) . Acute GVHD was successfully treated by methylprednisolone and anti-R-IL2 (inolimomab) and evolved towards residual liver cGVHD. A CT scan performed 12 months after transplantation showed a complete response (Figure 1c and 1f) . Liver cGVHD was present at least 12 months after transplantation and then disappeared. Because of an escalated mean of CA-125, she underwent one DLI every 2 months from month 18 to 22, with escalating doses. This treatment did not reactivate the cGVHD. A CT scan performed 2 years after transplantation showed disease relapse (Figure 1d ). She was then given four courses of chemotherapy (platin and paclitaxel) with partial response cGVHD and a reactivation of her cGVHD. She is still alive with very slowly evolving disease.
Patient C: She presented with recurrent disease with high levels of CA-125 and peritoneal metastases (Figure 2a ). She received a non-myeloablative conditioning regimen with 3 days of ATG and developed skin aGVHD at day 20 which resolved progressively until day 90. A CT scan showed partial response (Figure 2b ). An elevation in CA-125 was observed 1 month after the aGVHD had resolved. We gave three escalating doses of DLI. Ten days after the last one, she developed skin cGVHD which stabilized tumor pro- 
Patient D:
A CT scan performed before transplantation showed peritoneal metastases and retroperitoneal nodes (Figure 3a) . She received a non-myeloablative conditioning regimen with 3 days of ATG. Immediately after the treatment, her CA-125 level doubled, while compression of the ureters provoked renal insufficiency. At day 23, she developed grade 3 cutaneous acute GVHD which then evolved towards digestive tract aGVHD. Despite treatment with high doses of methylprednisolone, ATG and anti-R-IL-2, she died of toxicity at day 127. A CT scan showed partial response (Figure 3b) .
Patient E:
She presented with retroperitoneal tumor nodules ( Figure 4a ) and a CA-125 of 472 units. Conditioning consisted of non-myeloablative treatment with only 1 day of ATG. She received peripheral blood stem cells and cyclosporine alone as prophylaxis against GVHD. At day 14 post-transplantation, the patient developed grade 2 cutaneous acute GVHD, which was successfully treated by methylprednisolone. After a slow decrease of corticosteroids, she developed grade 3 aGVHD at day 35 and required treatment with high doses of methylprednisolone and anti-R-IL2 (inolimomab), which slowly controlled the aGVHD. At day 60 the CA-125 was 50.6 units and a CT scan showed a partial response (Figure 4b ).
Antitumor effects (graft-versus-ovarian cancer)
Tumor regression was seen in the four evaluable patients. There was a clear association between disease regression and presence of aGVHD. Patient A experienced a relapse of her disease after disappearance of the liver cGVHD. Patient C had controlled ovarian disease during her skin cGVHD, although after using methylprednisolone an obvious relapse was observed, 10 days after the beginning of the corticosteroids.
Effects of donor lymphocyte infusions
We gave escalating doses of DLI to patients A and C. DLI for patient A slightly worsened her dry skin and eyes, but was not very effective. She relapsed slowly 2 months after the last DLI. Two weeks after the third DLI, patient C experienced a return of the cutaneous GVHD. This reactivation was associated with tumor stabilization. The severe progression of the skin cGVHD required immunosuppressive treatment, and 10 days later she relapsed.
Survival analysis
Patient B does not provide any information regarding a potential graft-versus-ovarian cancer effect due to her early death.
Among the other four patients we observed one death due to aGVHD at day 127 (patient D). She had a stable partial response. Patient A relapsed after 24 months of complete response, and is the longest survivor to date at more than 3 years after transplantation. Patient C had a stable partial response (12 months) until we started methylprednisolone for her extensive cGVHD. Patient E is in partial response after 2 months.
We did not perform Kaplan-Meier survival curves due to the small size of our patient population.
Discussion
High-dose chemotherapy is based on the observation of a marked dose-response relationship for many cytotoxic agents. During recent years, this procedure has increasingly been used in conjunction with autologous stem cell rescue in patients with solid tumors, including ovarian cancers. Treatment-related mortality is low. However, even if this procedure is of interest in certain solid tumors, disease relapse is frequent. An escalating chemotherapy dose cannot completely eradicate the disease. Furthermore, the autologous graft might be contaminated by tumor cells. 36 According to the relative immunogenicity of ovarian cancers, this study has been developed with the expectation that graft-versus-tumor, like GVL, will have a significant anti-tumor effect. We found that despite their advanced refractory ovarian cancer, almost all patients experienced a response.
Several lines of evidence suggest that the observed regression of metastatic ovarian carcinoma was probably mediated by a graft-versus-tumor effect. Firstly, one patient received a myeloablative regimen while the other three evaluable patients received non-myeloablative regimens, which cannot explain the tumor regression. Secondly, there was a strong correlation between the occurrence and the persistence of GVHD and the antitumor effect. Lastly, in at least one patient we observed clear tumor stabilization after infusion of donor lymphocytes. Other graft-versus-tumor effects have been reported. [28] [29] [30] Ueno et al 29 reported 10 patients with metastatic breast cancer which involved the liver or bone marrow. They were treated with high-dose chemotherapy and allogeneic PBPC transplantation. They observed tumor regression in the majority of patients, and a strong correlation with the presence of GVHD. Eibl et al 28 demonstrated that allogeneic T lymphocytes collected during GVHD and cultivated were able to mediate a cytotoxic effect against breast cancer cell lines. Childs et al 30 reported graft-versus-tumor effects in patients suffering from kidney cancer. These tumors are known to be chemoresistant, but their immunogenicity has been demonstrated. All 19 patients received a non-myeloablative regimen. Ten patients showed a response after allogeneic PBPC transplantation. Our results suggest that, as reported with breast cancers and kidney cancers, graft-versus-ovarian cancer cells may have a significant antitumor effect.
Our results also suggest that allogeneic transplantation in ovarian cancer is a feasible procedure. The three different conditioning regimens resulted in similar regimen-related toxicities, aGVHD, occurrence of infections, chimerism and hematologic recovery. The four evaluable patients had durable engraftment with complete chimerism observed from day 30.
Patient B died 6 days after allogeneic transplantation. No treatment side-effects were observed. Before transplantation, her refractory ovarian cancer was progressive on chemotherapy. At the time of administration of ATG, her disease rapidly evolved. This tumor progression during non-myeloablative conditioning was also observed in patient D. This suggests that the immunosuppression and probably more specifically the autologous T cell depletion induced by ATG might positively influence tumor growth. The non-myeloablative regimen has to be carefully chosen as patients should be selected for non-progressive disease and life expectancy of more than 6 months. The antitumor effect of acute and/or chronic GVHD also requires time to develop. For these reasons, we treated our last patient with a single dose of ATG. Other non-myeloablative regimens have been reported, 30, [37] [38] [39] [40] [41] some of which do not use ATG. Thus, the use of ATG may not be necessary and this point merits consideration. Similarly, a reduction in the dose of fludarabine may be considered.
Of the two patients who were treated with DLI, one experienced recurrence of GVHD, associated with stabilization of her disease. This suggests a treatment benefit. As has been demonstrated in hematologic malignancies, DLI might provide good adoptive immunotherapy for some patients. [42] [43] [44] None of our patients had a durable complete response. Disease relapse appeared to be strongly correlated with the disappearance of GVHD. On the other hand, as observed in patient C, cGVHD persistence might affect life quality and induce problems such as opportunistic infections. The use of immunosuppressive agents for patient C probably inhibited immune antineoplastic mechanisms, which led to tumor progression. Keeping a balance between tolerable toxicity of cGVHD and antitumor effects is difficult. However, at this point, whether control of the tumor is due to a specific GVT or to an improvement in immunocompetence is unclear. It should also be mentioned that CA-125 may not be a reliable marker in the presence of GVHD of the gut.
Our results suggest that progression-free survival and global survival might be increased compared to results after conventional chemotherapy. However, it is too early to determine whether allogeneic transplantation in ovarian cancer is a good alternative.
We emphasize that this procedure requires further investigation. Additional patients and more follow-up time are required to better demonstrate a graft-versus-ovarian cancer cell effect. Furthermore, it is important to emphasize the substantial and sometimes fatal complications. Two of our patients died, one of uncontrolled aGVHD, and the other one of rapid disease progression which might have been provoked by the conditioning regimen. These complications should caution physicians in the choice of patients. Because of these limitations and the lack of long-term follow-up, this procedure should remain under investigation.
